Norden Group LLC Cuts Position in Hologic, Inc. (NASDAQ:HOLX)

Norden Group LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 23.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,805 shares of the medical equipment provider’s stock after selling 1,184 shares during the period. Norden Group LLC’s holdings in Hologic were worth $272,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Hologic in the fourth quarter worth $27,000. Venturi Wealth Management LLC acquired a new position in Hologic in the 3rd quarter valued at about $29,000. NBC Securities Inc. purchased a new position in Hologic in the 3rd quarter valued at about $33,000. Deseret Mutual Benefit Administrators boosted its stake in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its holdings in shares of Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 227 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Hologic stock opened at $76.28 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $86.74. The company has a market cap of $17.91 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 2.57 and a beta of 1.01. The stock’s 50-day moving average is $76.11 and its 200-day moving average is $72.93.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 earnings per share. Equities analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Raymond James upped their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and an average price target of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.